service@medevin.org

    • Services

    Antibody Drug Conjugates

    Antibody Drug Conjugates (ADCs) represent an emerging targeting technology that incorporates selective protein/receptor-binding monoclonal antibodies combined with a linker-payload to target and selectively kill diseased cells (i.e., cancer) without negatively impacting other areas of the body.

    Improving Treatment Options & Quality of Life

     

    Saving lives through cutting edge technology & operational know-how.

    Medevin CMO is one of only a select few with expertise in late stage scaleup and ADC contract manufacturing, coordinating either individual, or all collective elements of the complex ADC supply chain – from antibody intermediate to conjugation and final drug product fill finish, Medevin has the facilities and expertise to help clients succeed in advancing lead ADC drug candidates.

    Working with Medevin Contract Manufacturing means partnering with a proven innovator and market leader focused on advancing your development program to BLA and market success. We have extensive know-how and expertise in the most common types of linker-payload conjugation with a robust (ADC) supply chain planning process.

    Our global science and technology team and state-of-the-art facilities can help streamline your production processes and ensure successful scale-up. Medevin leverages a proven global quality and operational network to mitigate risk and ensure successful BLA and supply chain assurance.

    Speed with Precision

     

    Expertise to deliver quantity and quality. 

    World-Class Biologics Manufacturing:

    With patients’ lives on the line, biologics must be safe, reliable, and consistent. At Medevin Contract Manufacturing, we understand that, with large molecule drugs, speed-to-market is imperative, but so are efficiency and cost containment. Achieving these high production goals depends largely on the quality of the cell line at the heart of the process, which is tied directly to the CMO partner you choose.